Connect with us

Technology

eGlint Wins 2026 BioTools Innovator Grand Prize, Recognizing Its Breakthrough in Rapid, Distributed Proteomics

Published

4 days ago

on

Company awarded $250,000 Grand Prize at BioTools Innovator Capstone Competition, highlighting the potential of its ProteoNex™ biosensor platform to transform protein measurement across life science research, biomanufacturing, and clinical diagnostics.

SAN DIEGO, Oct. 19, 2026 /PRNewswire/ — eGlint, Inc., a biotechnology company developing next-generation extremely rapid proteomics technologies, today announced that it has been named the 2026 BioTools Innovator Grand Prize Winner, receiving the $250,000 top award at the BioTools Innovator Capstone Competition held October 14 in San Diego, California.

The award recognizes eGlint’s innovative approach to protein measurement and its potential to transform how researchers, biopharmaceutical manufacturers, and healthcare providers access critical biological information.

eGlint was selected as the winner following a live competition among four finalists—Caravel, Pando Bioscience, QuantumCyte, and eGlint—chosen from a highly competitive field of more than 550 applicants worldwide. The four finalists emerged from the 30-company 2026 BioTools Innovator accelerator cohort, which brought together promising emerging companies developing technologies to advance life science research, drug development, and diagnostics.

The Grand Prize Winner was selected through live audience voting by attendees that included life science industry executives, investors, strategic partners, and technology innovators.

Recognizing Innovation in Rapid Proteomics

eGlint is developing a new generation of distributed proteomics technologies designed to make quantitative protein measurement faster, more accessible, and more actionable.

At the core of the company’s technology is its proprietary ProteoNex™ biosensor platform, which uses engineered affinity reagents and thermal stability measurements to enable rapid, sensitive, and multiplexed detection of proteins and other biological molecules.

Unlike conventional protein measurement technologies that often require centralized laboratories, specialized equipment, and lengthy workflows, eGlint’s platform is designed to deliver quantitative results in approximately 10 minutes, enabling protein measurements closer to where and when decisions are made.

The platform supports three complementary product systems:

ProteoMix™: A rapid, multiplex protein measurement system compatible with existing quantitative PCR (qPCR) instruments, initially targeting research, biopharmaceutical development, and cell and gene therapy manufacturing applications.ProteoCare™: A point-of-care platform designed to enable rapid measurement of multiple biomarkers in clinical settings, with initial applications in critical care, ARDS, sepsis, and inflammatory disease monitoring.ProteoHome™: A miniaturized platform being developed to extend molecular testing into decentralized and at-home environments with just the use of a smartphone.

Together, these systems support eGlint’s vision of making proteomics a readily accessible source of real-time biological information, rather than a laboratory measurement that requires hours or days to obtain.

A Milestone for eGlint and the BioTools Innovator Community

“Winning the 2026 BioTools Innovator Grand Prize is an incredible honor, particularly given the outstanding quality of the other three finalists and the companies across the entire cohort,” said Robert W. Georgantas III, PhD, Chief Executive Officer of eGlint.

“The BioTools Innovator program has been an extraordinary experience for our team. The mentorship, engagement with our peers, and access to industry expertise and resources have been transformative, helping us accelerate our first product launch and sharpen our commercialization strategy. We are truly grateful to the BioTools Innovator team, our mentors, and the broader cohort for their support, and we are proud to be part of the BTI family.”

The 2026 BioTools Innovator program brought together 30 companies selected through a rigorous evaluation process involving industry leaders, investors, and more than 120 judges from across the life sciences ecosystem.

Throughout the accelerator, participating companies received individualized mentorship, strategic guidance, industry connections, and opportunities to engage with potential customers, partners, and investors.

eGlint also participated in the BioTools Innovator wraparound Vanguard Accelerator, which supports technologies with potential applications in deploying innovative medical countermeasures that enhance the United States’ preparedness and response posture against health security threats in line with BARDA’s mission.

Accelerating the Commercialization of Real-Time Proteomics

The Grand Prize comes as eGlint advances the commercialization of ProteoMix, its first product system, while continuing development of its point-of-care and decentralized diagnostic platforms.

ProteoMix enables rapid, multiplex protein measurements using widely available qPCR instrumentation, eliminating the need for customers to purchase dedicated new analytical equipment.

The company’s initial commercial focus includes cell and gene therapy development and manufacturing, where rapid measurement of cytokines and other protein biomarkers could substantially improve process monitoring, quality control, and manufacturing decision-making.

By reducing the time required for protein measurements from hours to minutes, eGlint aims to help researchers and manufacturers make more timely, data-driven decisions while reducing workflow complexity and analytical costs.

Looking ahead, the company plans to extend its biosensor technology into clinical applications, where rapid measurement of inflammatory and other disease-associated biomarkers could support more timely diagnosis, patient monitoring, and personalized treatment strategies.

“This recognition comes at an important moment for eGlint as we move from technology development toward commercialization,” added Georgantas. “Our goal is to fundamentally change how and where proteins are measured, making high-quality proteomic information available in minutes, wherever it is needed. Winning the BioTools Innovator Grand Prize reinforces the importance of that mission and provides additional momentum as we bring our first products to market.”

About eGlint

eGlint, Inc. is a biotechnology company developing next-generation distributed proteomics technologies to make protein measurement faster, more accessible, and more actionable. Built on its proprietary ProteoNex™ biosensor platform, eGlint’s ProteoMix™, ProteoCare™, and ProteoHome™ systems are designed to enable rapid, sensitive, multiplexed protein measurements across life science research, biopharmaceutical manufacturing, clinical diagnostics, and decentralized healthcare. By reducing the time from sample collection to actionable biological information, eGlint aims to transform how proteins are measured and used to guide scientific and medical decisions.  For more information about eGlint, visit the website and follow the organization on LinkedIn.

About BioTools Innovator

Based in Los Angeles, BioTools Innovator was established to advance cutting-edge research and improve human health by accelerating the growth of a broad spectrum of life science tools and diagnostics. BioTools Innovator matches industry leaders with innovative early-stage and emerging growth biotechnology-focused companies for mentorship and support.

BioTools Innovator is powered by MedTech Innovator (MTI), the world’s largest accelerator of medical technology companies and the premier nonprofit startup accelerator in the medical technology industry. To date, MTI alumni have collectively brought over 500 products to market and raised $12+ billion in follow-on funding. For more information about BioTools Innovator, visit the website and follow the organization on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/eglint-wins-2026-biotools-innovator-grand-prize-recognizing-its-breakthrough-in-rapid-distributed-proteomics-302912885.html

SOURCE eGlint, Inc.

Related Topics:
Continue Reading

Technology

LEAP Group Relaunches HumanView, a Growth Intelligence System Built to Explain Why Customers Behave the Way They Do

Published

2 hours ago

on

October 24, 2026

By

Reimagined from the ground up, HumanView pairs statistical modeling with expert analysts to turn millions of real-world customer signals into business decisions

LOUISVILLE, Ky., Oct. 23, 2026 /PRNewswire/ — LEAP Group today announced the relaunch of HumanView, its growth intelligence service. The new version has been rebuilt from the ground up and now has a dedicated home at leapgroupnetwork.com/humanview.

HumanView analyzes what customers say and do across social platforms, e-commerce sites, review platforms, search behavior and user-generated content, including signals from Reddit, TikTok, YouTube, Meta, Amazon and Walmart+ that general AI tools cannot always access. Because the data reflects unprompted, real-world behavior, it avoids the response bias built into surveys and focus groups.

The service works in three layers. HumanView captures signals at scale, decodes millions of records through validated statistical models such as regression, correlation and clustering, and then relies on experienced analysts to interpret the patterns. Clients receive clear, human-validated insights instead of another dashboard.

“Machines find the patterns. Humans find the point,” said Alan Gilleo, CEO at LEAP Group. “The first version of HumanView showed us how much customers reveal when nobody is asking them questions. This version is built to explain why they act the way they do, and to put those answers in front of everyone making decisions, from product to service to marketing.”

HumanView focuses on three areas:

Growth Intelligence: customer motivations and how people perceive a brand and its competitors

Market and Category Intelligence: product pain points, service friction, unmet needs and competitive gaps

Audience Intelligence: new segments, positioning opportunities and gaps in the market

Every model is designed and validated by data scientists and benchmarked before it informs a recommendation.

To learn more about HumanView, visit leapgroupnetwork.com/humanview.

About LEAP Group
LEAP Group is a boutique marketing agency holding company with offices in Louisville, Indianapolis, Cincinnati and Chicago. Guided by the belief that brands should “Market Less. Matter More.,” LEAP gives clients access to specialized experts across its entire network. Learn more at leapgroupnetwork.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-group-relaunches-humanview-a-growth-intelligence-system-built-to-explain-why-customers-behave-the-way-they-do-302918557.html

SOURCE LEAP Group

Continue Reading

Technology

STEPHEN A. SMITH ADDRESSES WHITE HOUSE DINNER ATTENDANCE, REAFFIRMS COMMITMENT TO HBCUs AND PROTECTING CORPORATE INVESTMENT IN BLACK EDUCATION

Published

3 hours ago

on

October 24, 2026

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Stephen A. Smith, media mogul, New York Times bestselling author, and proud 1991 graduate of Winston-Salem State University, is addressing the public discussion surrounding his decision to attend a White House dinner with President Donald Trump, emphasizing his commitment to the long-term financial stability of Historically Black Colleges and Universities (HBCUs).

For Smith, the decision was rooted in a commitment to institutions that have educated generations of Black leaders, professionals, entrepreneurs, and public servants.

“I will always advocate for HBCUs and the students whose futures depend on them,” Smith said. “My reason for attending the White House dinner was to discuss the challenges these institutions face in securing long-term funding and to make the case that corporate America must continue to invest in them.”

Smith acknowledged federal support through the FUTURE Act while expressing concern that political tensions surrounding diversity, equity, and inclusion (DEI) could discourage private companies from supporting HBCUs. He maintains that these institutions deserve sustained corporate partnerships, philanthropic contributions, and public investment.

“If we truly believe in free-market capitalism, businesses should be able to support educational institutions and charitable causes without fear of criticism or repercussions,” Smith said. “HBCUs have made extraordinary contributions to this country. They deserve sustained public and private investment.”

Ashley Christopher, Esq., Founder and CEO of the HBCU Week Foundation, recognized Smith’s advocacy and decision to engage with the administration.

“Stephen A. Smith has been a powerful advocate for HBCUs, using his platform and influence to shine a national spotlight on our institutions,” expressed Christopher, “His continued support of HBCU Week helps advance our mission of connecting students with life-changing educational opportunities, and we are proud to have him as our ambassador.”

Since Smith became an HBCU Week Ambassador in 2019, the initiative has facilitated more than 15,000 on-the-spot college acceptances and raised and awarded more than $150 million in scholarships, according to the HBCU Week Foundation.

As public discussion continues, Smith is emphasizing the importance of ensuring HBCUs have the resources and partnerships needed to educate future generations and expand opportunities for students.

CLICK HERE to watch Smith’s full response to his White House visit.

MEDIA CONTACT:

media@mrsasinc.com

View original content:https://www.prnewswire.com/news-releases/stephen-a-smith-addresses-white-house-dinner-attendance-reaffirms-commitment-to-hbcus-and-protecting-corporate-investment-in-black-education-302918547.html

SOURCE Straight Shooter Media

Continue Reading

Technology

Advantex Announces Completion of Financing and Extension of Maturity Date of Previously Issued Debentures

Published

3 hours ago

on

October 24, 2026

By

TORONTO, Oct. 23, 2026 /CNW/ — Advantex Marketing International Inc. (CSE: ADX) (“Advantex”), a leader in the merchant cash advance and loyalty marketing products for merchants, today announced the completion of a $250,000 secured debt financing. Advantex issued a $250,000 non-convertible debenture which bears an interest rate at 12% per annum and matures December 15, 2027. The proceeds raised from this issuance of the Debenture will be used for working capital purposes.

Advantex has also extended the maturity of its existing $700,000 in 12% secured debentures from October 10, 2026 to December 15, 2027.

About Advantex Marketing International Inc.

Advantex provides working capital to merchants. Advantex also provides specialized marketing programs that enable members of Aeroplan to earn Aeroplan points at participating merchants.

Advantex shares trade on the Canadian Securities Exchange under the symbol ADX. For more information go to Advantex’s profile on www.sedar.com

Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable securities laws relating to the future business and operations of Advantex. Actual results and developments may differ materially from those contemplated by these statements. The business and operations of Advantex described herein is dependent on a number of factors and is subject to a number of risks and uncertainties. Factors that could cause actual results to differ material include, but are not limited to, changes in Advantex’s economic and competitive conditions including but not limited to the industry sectors in which Advantex operates.

The statements in this news release are made of the date of this release. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and Advantex undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law.

SOURCE Advantex Marketing International Inc.

Continue Reading

Trending